10x Genomics, Inc.
10x Genomics, Inc.
Your view on TXG
Overview
What the company does, where it operates, and who runs it.
About 10x Genomics, Inc.
- Industry
- Medical - Healthcare Information Services
- Sector
- Healthcare
- CEO
- Serge Saxonov
- Headquarters
- 6230 Stoneridge Mall Road, Pleasanton, CA, US
- Industry
- Medical - Healthcare Information Services
- Sector
- Healthcare
- CEO
- Serge Saxonov
- Headquarters
- 6230 Stoneridge Mall Road, Pleasanton, CA, US
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific.
The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment.
The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions.
The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for 10x Genomics, Inc., and the rating behind it. TXG last traded at $97.74; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for 10x Genomics, Inc.. Starting points for 10x Genomics, Inc.: EPS -$0.58, beta 2.08 — an Medical - Healthcare Information Services name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for 10x Genomics, Inc.. 10x Genomics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for 10x Genomics, Inc.. Trailing twelve-month EPS for 10x Genomics, Inc. stands at -$0.58. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for 10x Genomics, Inc.. 10x Genomics, Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
10x Genomics, Inc. valued side by side against its closest peers. 10x Genomics, Inc. is measured against Medical - Healthcare Information Services peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold 10x Genomics, Inc., and how their positions are changing. At a $12.41B market value, institutional positions materially move 10x Genomics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by 10x Genomics, Inc. executives and directors. Shares of 10x Genomics, Inc. have traded between $6.78 and $17.70 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming 10x Genomics, Inc.. 10x Genomics, Inc. is a $12.41B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming 10x Genomics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for 10x Genomics, Inc.. Coverage tracks 10x Genomics, Inc. within Medical - Healthcare Information Services (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.